News|Articles|November 17, 2026

Orlando Forum Weighs Dual Antiplatelet Therapy Duration After Stroke

Listen
0:00 / 0:00

Key Takeaways

  • Recurrence despite standard antiplatelet regimens remains clinically meaningful, highlighting limitations of repeatedly cycling aspirin, clopidogrel, and related strategies without addressing residual mechanistic risk.
  • Practice drift leads to prolonged aspirin–clopidogrel exposure when stop dates are omitted; guideline-concordant windows are typically 21 days post–minor stroke/high-risk TIA and 90 days for intracranial atherosclerosis.
SHOW MORE

At an HCPLive and NeurologyLive Clinical Forum in Orlando, David Z. Rose, MD, of USF Morsani College of Medicine, discussed residual recurrence risk, dual antiplatelet therapy duration, and factor XIa inhibition in noncardioembolic stroke.

On October 14, 2026, HCPLive and NeurologyLive convened a Clinical Forum in Orlando, Florida, bringing together neurologists and a cardiologist to discuss secondary prevention after noncardioembolic ischemic stroke and transient ischemic attack (TIA). The program, “Rethinking Secondary Stroke Prevention: New Evidence, Emerging Therapies, and Care Coordination in Non-Cardioembolic Ischemic Stroke and Transient Ischemic Attack,” was led by David Z. Rose, MD, a vascular stroke neurologist and professor at the University of South Florida (USF) Morsani College of Medicine. The program was independently produced with support from Bayer Healthcare Pharmaceuticals.

Rose opened by noting that recurrence among patients on guideline-directed antiplatelet therapy still falls between roughly 5% and 8%. “We think we’re doing everything by the book, by the guidelines, and yet we still have this pretty high recurrence rate,” he told the group. Of decades of antiplatelet trials, he said, “That’s what we’re kind of doing, shuffling the deck chairs around the Titanic. The ship’s still sinking.”

Much of the evening centered on how dual antiplatelet therapy (DAPT) is applied in practice. Rose emphasized that DAPT with aspirin and clopidogrel (Plavix) is generally limited to 21 days after minor stroke or high-risk TIA, extending to 90 days for intracranial atherosclerosis. Attendees described a different reality in the community. “What I see most often is a knee-jerk reaction to do aspirin and Plavix,” one neurologist said, adding that discharge orders rarely carry an end date and primary care physicians often simply refill them. Several attendees favored CYP2C19 loss-of-function testing during admission to guide use of ticagrelor (Brilinta) over clopidogrel.

Rose pushed back on escalating antithrombotic therapy after a recurrent event without revisiting the cause. “Stroke is not an accident. It happens for a reason or a variety of reasons,” he said, urging a complete vascular and cardiac workup. He pointed to inpatient loop recorder implantation for cryptogenic stroke as a priority, noting that at his center only 14% of patients referred for outpatient monitoring completed it. “Not being able to tolerate or take [anticoagulation] is not an excuse to not do a loop in the cryptogenic population, in my opinion,” he said, citing left atrial appendage closure as an alternative.

The discussion then turned to factor XIa (FXIa) inhibition. Rose reviewed the phase 3 OCEANIC-STROKE trial (NCT05686070), in which asundexian (Sunharbo; Bayer) 50 mg added to single or dual antiplatelet therapy reduced recurrent ischemic stroke compared with placebo (6.2% vs 8.4%; HR, 0.74; 95% CI, 0.65-0.84) in more than 12,000 patients, without a significant difference in major bleeding. “We haven’t had a good trial like this in this space in the past 25 years,” he said. “Adding a blood thinner doesn’t cause bleeding. It’s almost too good to be true.” “If you see 100 patients, you’ll prevent maybe 2 more strokes,” he added. Milvexian, another oral FXIa inhibitor, remains under study in the ongoing phase 3 LIBREXIA-STROKE trial (NCT05702034).

Attendees raised practical questions about drug interactions, adherence in patients with cognitive impairment, polypharmacy, and coverage. Rose cautioned against substituting an FXIa inhibitor for one component of DAPT. “That’s not what was studied,” he said. On cost, he added, “It has to be priced right. It can’t be too expensive.” On November 9, 2026, less than a month after the forum, the FDA approved asundexian in combination with antiplatelet therapy for this population.

In closing, attendees emphasized earlier neurology follow-up after discharge, clearer protocols for primary care, and in-hospital genotyping. “It’s not just diagnose and adios anymore, it’s complicated. But as neurologists, we have to think in terms of not just treatment but prevention,” one neurologist said.

Interested in attending a future NeurologyLive Clinical Forum?

NeurologyLive Clinical Forums are regional, peer-to-peer roundtable discussions led by expert moderators. Neurologists interested in attending a future forum can view upcoming events on the NeurologyLive Live Events page or contact events@neurologylive.com.


Related to this article

Awareness, Not Access, Remains the Barrier to NF1 Therapy
At a NeurologyLive Clinical Forum, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how patients with NF1-associated plexiform neurofibromas get recognized, referred, and treated.